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Abstract
Background: Pulsus paradoxus estimated by dynamic change in area under the oximeter plethysmograph
waveform (PEP) might provide a measure of acute asthma severity. Our primary objective was to determine how
well PEP correlates with forced expiratory volume in 1-second (%FEV1) (criterion validity) and change of %FEV1
(responsiveness) during treatment in pediatric patients with acute asthma exacerbations.
Methods: We prospectively studied subjects 5 to 17 years of age with asthma exacerbations. PEP, %FEV1, airway
resistance and accessory muscle use were recorded at baseline and at 2 and 4 hours after initiation of
corticosteroid and bronchodilator treatments. Statistical associations were tested with Pearson or Spearman rank
correlations, logistic regression using generalized estimating equations, or Wilcoxon rank sum tests.
Results: We studied 219 subjects (median age 9 years; male 62%; African-American 56%). Correlation of PEP with
%FEV1 demonstrated criterion validity (r = - 0.44, 95% confidence interval [CI], - 0.56 to - 0.30) and responsiveness
at 2 hours (r = - 0.31, 95% CI, - 0.50 to - 0.09) and 4 hours (r = - 0.38, 95% CI, - 0.62 to - 0.07). PEP also correlated
with airway resistance at baseline (r = 0.28 for ages 5 to 10; r = 0.45 for ages 10 to 17), but not with change over
time. PEP was associated with accessory muscle use (OR 1.16, 95% CI, 1.11 to 1.21, P < 0.0001).
Conclusions: PEP demonstrates criterion validity and responsiveness in correlations with %FEV1. PEP correlates with
airway resistance at baseline and is associated with accessory muscle use at baseline and at 2 and 4 hours after
initiation of treatment. Incorporation of this technology into contemporary pulse oximeters may provide clinicians
improved parameters with which to make clinical assessments of asthma severity and response to treatment,
particularly in patients who cannot perform spirometry because of young age or severity of illness. It might also
allow for earlier recognition and improved management of other disorders leading to elevated pulsus paradoxus.
Background
Clinicians have few objective measures to evaluate acute
asthma severity and are likely to under-treat these epi-
sodes[1-6]. A severity measure should correlate with an
accepted criterion standard (criterion validity) and quan-
tify clinically important changes of this standard over
time (responsiveness)[7].
Spirometry is the criterion standard for assessing the
severity of airway obstruction (% predicted FEV1,
%FEV1) but is effort dependent and not available in
most acute care settings[8,9]. Airway resistance is
another measure of lung function. Portable devices for
m e a s u r e m e n to fa i r w a yr e s i s t a n c eb yt h ei n t e r r u p t e r
technique (Rint) are available and require only tidal
breathing. Rint has been demonstrated to correlate with
%FEV1 a n ds p e c i f i ca i r w a yr e s i s t a n c eb yb o d yb o x
plethysmography[10-13].
Accessory muscle use has been shown to be associated
w i t hac l i n i c a l l ym e a n i n g f u ld e c r e a s ei n% F E V 1[14,15].
However, though accessory muscle use gives an indica-
tion of work of breathing, it does not provide a precise
measure of airflow limitation.
Measurement of pulsus paradoxus (PP) during acute
asthma exacerbations is currently recommended by
national and international guidelines [16,17]. However,
manual determination of PP is difficult, particularly in
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ments[18-21]. More than 98% of providers do not use
this measurement at the bedside[22].
The pulse oximeter plethysmograph waveform closely
mirrors radial artery Doppler waveforms, and previous
investigations have provided evidence supporting the
use of oximeter plethysmograph waveform data to esti-
mate PP[23-28]. Developing methods to objectively
quantify plethysmograph waveform data is clinically
relevant as it might provide a non-invasive and continu-
ous estimate of the severity of airway obstruction or
other physiologic disturbances contributing to PP.
Objective
Our primary objective was to determine how well a
mathematic model for plethysmograph estimation of
pulsus paradoxus physiology (PEP) correlates with
%FEV1 (criterion validity) and change of this criterion
standard (responsiveness) during treatment in pediatric
patients with acute asthma exacerbations. Secondary
objectives were to determine the correlation of PEP with
airway resistance and accessory muscle use.
Methods
Study design and study population
We enrolled a prospective convenience sample of sub-
jects ages 5 to 17 years with doctor-diagnosed asthma,
signs or symptoms of an asthma exacerbation, (cough,
dyspnea, shortness of breath, wheezing and/or chest
pain),[29] and need for treatment with systemic corti-
costeroid (CCS) and inhaled albuterol as determined by
the pediatric emergency medicine attending. The setting
was an urban, academic, tertiary care children’s hospital
emergency department (PED). We excluded patients
with pneumonia by clinical or radiographic criteria.
Enrollment hours were 7 am to 10 pm weekdays and
approximately every 3
rd weekend day. The Vanderbilt
University Institutional Review Board approved the
study protocol and a waiver of immediate informed con-
sent such that baseline variables could be obtained prior
to the informed consent process.
Study protocol and measurements
All study data was collected by the principal investigator
(DHA) or research assistant (DJR). The principal investi-
gator trained the research assistant in the study proto-
col, and both individuals received training in portable
spirometry performance by pediatric pulmonary func-
tion technicians. The investigators were not masked to
study data during data acquisition.
At enrollment we recorded demographic information,
medical history, family asthma history, asthma medica-
tion use, asthma symptom history, and Global Initiative
for Asthma (GINA) chronic asthma control[16]. All
other variables were obtained prior to administration of
CCS (baseline) and bronchodilator treatments and again
at 2 and 4 hours after CCS administration if the subject
remained in the PED at that time.
PEP was determined at baseline, 2 and 4 hour time
points as follows (figure 1)[30]. First, a Novametrix oxy-
pleth pulse oximeter (Respironics Novametrix, Walling-
ford, CT) was configured to output the raw, high
resolution waveform derived from the sensor’s 940 nm
infrared (IR) signal. We used this raw, unfiltered,
unsmoothed signal in order to capture the full variability
in waveform morphology during the respiratory cycle.
This digitized IR signal was fed to a laptop computer via
a serial cable and processed with a real-time, dedicated
waveform analysis algorithm built for this purpose using
graphical measurement and analysis software (LabVIEW
7.1, National Instruments, Austin, TX). Second, the
plethysmograph waveform, constructed from the IR sig-
nal, was interrogated at 100 Hz. The software algorithm
then calculated area under the curve (AUC) for each
cardiac cycle as the area under the waveform bounded
by the point of deflection from baseline to the point of
return to baseline. During each successive 3-second
time interval the smallest and largest AUC were identi-
fied and the percent AUC difference calculated (ΔAUC).
Individual waveforms with AUC beyond 2 SD of a 180
second moving average were treated as artifact and
excluded from further calculation. We chose the 3-sec-
ond interrogation interval in an effort to include a full
respiratory cycle because we anticipated that our sub-
jects would have respiratory rates ≥ 20/min. Finally, the
moving average of the 60 most recent ΔAUC (a 180-sec
period) provided output of PEP.
We applied the oximeter sensor to a finger for PEP
data acquisition. The subject was asked to keep the
hand still and to not talk. This was necessary because
the unprocessed IR signal is subject to movement arti-
fact. We acquired PEP data over a minimum of 5 min-
utes to allow the graphical output of PEP to stabilize.
The PEP value at the end of this period was recorded
and is expressed as a percent value.
Outcome measures
We used %FEV1 as the criterion standard to assess the
diagnostic accuracy of PEP and used airway resistance
and accessory muscle use as secondary severity mea-
sures. Accessory muscle use was defined as any visible
use of the scalene, sternocleidomastoid, suprasternal,
intercostal or subcostal muscles.
We measured airway resistance using a MicroDirect
MRT6000 module (Micro Medical, Kent, England). This
measurement was made prior to spirometry because the
forced vital capacity maneuvers for spirometry can tem-
porarily alter airway tone and airway resistance
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subject to breathe comfortably while supporting the
cheeks and submental tissue and extending the neck
slightly[32]. Five measurements during exhalation were
made and the median value recorded. The device calcu-
lates % predicted values for subjects ages 5 to 10 years
(%Rint) using the McKenzie standards and outputs
absolute values for subjects 11 years of age and above
(aRint)[33].
We used a MicroDirect MicroLoop spirometer for %
FEV1 determination. After applying a nose clip we
instructed each subject to perform forced vital capacity
maneuvers in accordance with American Thoracic
Society (ATS) 1994 spirometry standards.
9 %FEV1 was
calculated based on Knudson standards[34,35].
Some subjects could not perform 3 forced vital capa-
city maneuvers for each trial in accordance with ATS
criteria because of the severity of acute asthma or young
age. However, some of these trials included one or two
maneuvers with acceptable flow-volume and volume-
time curves.
A pulmonary function test oversight committee
reviewed these non-ATS trials to determine if any of the
data should be included in the analysis. This committee
included a pulmonary physiologist and a pediatric pul-
monary function lab technician (RRT). Each member
recorded their determination whether a non-ATS trial
should be retained for analysis based on the flow-
volume and volume-time curves. Committee members
were blinded to all other subject data and to the other
member’s determination. A non-ATS trial was retained
for data analysis if both members independently deter-
mined that it should be retained.
Sample size
We considered a correlation coefficient of 0.30 or greater
to be clinically relevant based on the study of Wright and
colleagues in which measurement of PP calculated from
change in height of finger arterial pressure monitor wave-
forms was correlated with %PEF (r = - 0.31)[36]. A sam-
ple size of 82 subjects would enable us to detect a
correlation coefficient of 0.35 or greater between PEP
Figure 1 Plethysmograph Estimate of Pulsus Paradoxus Calculation. 1) AUC is calculated for each cardiac cycle from plethysmograph
waveform. 2) ΔAUC is calculated for each successive 3-sec interval. 3) PEP is 180-sec moving average of ΔAUC.
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sided significance level of 0.05 (a =0 . 0 5 ) .W es e to u r
sample size at a minimum of twice this calculated value
in order to account for incomplete data. We anticipated
that we would achieve the necessary sample size over a
12 month period and chose this enrollment period to
minimize spectrum bias in seasonal asthma etiology and
severity.
Statistical analysis and data management
Descriptive statistics are presented as mean (SD) or
median (IQR), as appropriate. We compared our study
sample to the patient population ages 5 to 17 years seen
in the PED during the study period with a final diagno-
sis code (ICD 493) of asthma exacerbation. This popula-
tion data was extracted from a database designed
primarily for billing purposes. While not directly com-
parable to our study sample, this data would provide a
sense of how representative our sample was of the over-
all population meeting study inclusion criteria.
Differences, proportions, and correlations are reported
as point estimates, bounded by 95% confidence intervals
(CI). Analyses involving airway resistance are done sepa-
r a t e l yf o rs u b j e c t sa g e s5 - 1 0( % R i n t )a n da g e s1 1t o1 7
(aRint) years. The internal validity of PEP versus %FEV1
and PEP versus airway resistance at baseline was
assessed using the Pearson product-moment correlation
coefficient. The strength of the relationship between the
proportionate change in PEP and the proportionate
change in %FEV1 or the proportionate change in airway
resistance was assessed using the Spearman’s rank corre-
lation coefficient. The relationship between PEP and
accessory muscle use (present/not present) was exam-
ined in two ways. First, a logistic regression model using
generalized estimating equations to account for repeated
measures on a subject was used to assess the relation-
ship between PEP and accessory muscle use, adjusting
for time and any interaction it may have with changes
in PEP. Second, Wilcoxon Rank Sum tests were used at
each time point to determine whether the distribution
of PEP values differ between those with accessory mus-
cle use and those without.
All analyses were performed with R, version 2.8.1[37].
Study data were managed using REDCap (Research
Electronic Data Capture) electronic database[38]. We
have reported all 25 checklist items of the Standards for
Reporting of Diagnostic Accuracy (STARD) initiative
and have included a flow diagram (figure 2) to clarify
subject recruitment and study implementation. Addi-
tionally, we included all data, including possible outliers,
in the statistical analysis. We verified that the data met
all assumptions for the statistical methods used.
Results
Descriptive statistics
During the enrollment period (June 8, 2008 to June 7,
2009), we recruited 249 subjects for this study, and 219
subjects are included for analysis (table 1 and figure 2).
No subject experienced an adverse event as a result of
study participation. Age, gender and race of subjects
Figure 2 Identification Study Subjects.
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presented to our PED with an asthma exacerbation dur-
ing the study period (table 1). Median respiratory rates
(IQR) were 24/min (21-29) at baseline, 24/min (20-27)
at 2 hours, and 24/min (21-26) at 4 hours. The numbers
of subjects studied decreased at the 2 and 4 hour time
points (table 2) as subjects were discharged to home or
admitted to hospital. PEP improved between baseline
and 2 hours (median 38% and 35%), in parallel with
improvement in %FEV1 (median 61% and 69%), yet
these improvements were not apparent in the group
remaining at 4 hours (PEP median 38%; %FEV1 median
63%). Similar patterns are noted for airway resistance.
These measures of lung function indicate that the subset
of subjects remaining in the PED at later time points
either improved more slowly or not at all.
Associations with outcome measures
The correlations between PEP and %FEV1 and airway
resistance are included in table 3 and are displayed gra-
phically in figure 3. The confidence intervals for the cor-
relations of PEP with %FEV1 at baseline and for
proportionate changes over time do not span 0. These
correlations indicate internal validity of PEP values with
the primary criterion standard. Statistically significant
correlations between PEP and airway resistance were
noted at baseline but not for change of these variables
over time.
A logistic regression model using generalized estimat-
ing equations was used to assess the relationship
between accessory muscle use and PEP, adjusting for
time. There was a statistically significant association of
increased PEP and accessory muscle use (OR 1.16, 95%
CI, 1.11 to 1.21, P < 0.0001). In addition, the model
indicated that this association differed over time as seen
by the significant interaction term (P < 0.0001). How-
ever, this result should be viewed cautiously given the
small number of subjects who remained in the PED and
had both 4 hour measurement of PEP and accessory
muscle use at that time (n = 9). Wilcoxon Rank Sum
tests were also used to assess the relationship of PEP
with accessory muscle use at each time point. Test
results for each time point across the groups were
Table 1 Subject and Study Population Demographic and
Clinical Characteristics
Variable PED Asthma
Population*
(n = 1,060)
Study
Subjects
(n = 219)
Age, median (IQR) 8.9 (6.9 - 11.7) 9.0 (6.9 - 11.9)
Male gender 625 (59) 135 (62)
Race†
White 367 (34.6) 85 (39)
African-American 599 (56.5) 122 (56)
Hispanic 70 (6.6) 12 (5)
Other 24 (2.3) 0
Baseline PAS‡ NA§ 5 (2 - 8)
Prior PICU admission NA§ 42 (19)
Prior endotracheal intubation
for asthma
NA§ 10 (5)
Disposition from pediatric ED NA§
Discharge to home 181 (83)
Admit to floor bed 25 (11)
Admit to PICU 13 (6)
Data are presented as the numbers (percentage) unless otherwise indicated.
*PED Asthma Population: all patients ages 5 to 17 years presenting to
pediatric emergency department during study period with final primary
diagnosis of asthma exacerbation by ICD code 493, including study sample.
†Race and Ethnicity for study subjects are categorized according to NIH notice
NOT-OD-01-053. This does not include a category “Other.”
‡Pediatric Asthma Score, Median (IQR)
§Not available in database used to identify PED asthma population
Table 2 Predictor and Outcome Variable Measurements
Variable Baseline*
(n = 219)
2 Hour*
(n = 138)
4 Hour*
(n = 58)
Predictor
PEP† 38 (31 - 44, 214) 35 (29 - 40, 136) 38 (31 - 43, 57)
Outcomes
%FEV1‡ 61 (42 - 80, 148) 69 (52 - 82, 100) 63 (47 - 81, 46)
Airway resistance
Age 5 to 10 yr‡ 178 (142 - 241, 150) 143 (124 - 172, 93) 141 (124 - 161, 39)
Ages ≥ 11 yr§ 0.71 (0.56 - 0.94, 67) 0.59 (0.44 - 0.75, 44) 0.68 (0.56 - 0.80, 19)
Access. M. Use¶ 105 (48) 38 (28) 9 (16)
Data are presented as medians (IQR, number of non-missing values)
*Baseline value is before corticosteroid (CCS) administration. Two and 4 hour time points are times from CCS administration.
†PEP is Plethysmograph Estimate of Pulsus Paradoxus physiology. PEP values represent percent change in the plethysmograph waveform and have no unit
values.
‡Percent predicted value
§ Absolute value (kPa/L/s)
¶Number of non-missing values (%) of subjects with any visible use of the scalene, sternocleidomastoid, suprasternal, intercostal or subcostal muscles
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hours (P = 0.006), but not at 4 hours (P = 0.28). That
this association was not statistically significant at
4 hours may be due to the small sample size at that
time point (n = 57).
Discussion
We found that the use of quantified pulse oximeter
plethysmograph waveform data (PEP), a continuous,
real-time and effort-independent measurement, corre-
lates with %FEV1 (criterion validity, r = -0.44) as well as
with proportionate changes in %FEV1 over the first 2
and 4 hours (responsiveness, r = - 0.31 and - 0.38) of
acute asthma treatment in a PED. This compares favor-
ably with the findings of Wright and colleagues who
estimated PP based on change in waveform height and
found correlation with %PEF (r = - 0.31)[36]. In our
investigation we utilized %FEV1, the widely accepted
criterion standard of acute asthma severity, in addition
to secondary severity measures. We noted statistically
significant correlations between PEP and airway resis-
tance at baseline but not over time, and between PEP
and accessory muscle use at baseline and over time.
There are limitations of this study. First, the three out-
come measures may not fully reflect lung function, par-
ticularly in patients in significant respiratory distress.
Spirometry is highly effort dependent. Although we
ascertained the validity of each test by ATS criteria and
review of flow-volume loops, some subjects may not
have performed well due to respiratory distress or
young age. Additionally, % predicted values of Rint for
children ages 5 to 10 years of age are derived from a
small sample (n = 236) of healthy children of four ethni-
cities and may not be a valid outcome measure[33]. Sec-
ond, the raw, unfiltered, unsmoothed IR light signal
must be used for waveform analysis in order to fully
Table 3 Correlations of Plethysmograph Estimate of Pulsus Paradoxus Physiology with %FEV1 and Airway Resistance
Outcome variable Baseline*
(r, 95% CI)
Baseline to 2 Hr change*
(r, 95% CI)
Baseline to 4 Hr change*
(r, 95% CI)
%FEV1† -0.44 (-0.56, -0.30)‡ -0.31(-0.5, -0.09) -0.38 (-0.62, -0.07)
Airway resistance
Age 5 - 10 yr† 0.28 (0.12, 0.42)‡ 0.06 (-0.16, 0.28) ¶ 0.19 (-0.13, 0.51) ¶
Ages ≥ 11 yr§ 0.45 (0.23, 0.63)‡ 0.21 (-0.13, 0.52) ¶ 0.25 (-0.24, 0.66) ¶
Values are Spearman rank correlation coefficient unless otherwise specified.
*Baseline value is before corticosteroid (CCS) administration. Two and 4 hour time points are times from CCS administration. Correlations at 2 and 4 Hr are for
proportionate changes of PEP.
†Percent predicted baseline value and proportionate change of this value at 2 and 4 hr
‡ Pearson correlation coefficient (95% confidence intervals)
§Absolute baseline value (kPa/L/s) and proportionate change of this value at 2 and 4 hr
¶Numbers in parentheses are 95% confidence intervals derived using 1000 bootstrap replications.
Figure 3 Correlation of Plethysmograph Estimate of Pulsus Paradoxus with %FEV1 and Airway Resistance at baseline. Horizontal axes in
each panel are plethysmograph estimates of pulsus paradoxus (PEP) expressed as %. Vertical axes are percent predicted values for FEV1 and
airway resistance (ages 5 to 10 years) and absolute value (kPa/L/s) for airway resistance (ages 11 to 17 years).
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artifact was possible, and signal stabilization methods
might be employed to minimize this artifact. Third, out-
liers were noted (figure 3), possibly from movement arti-
fact or individual differences in the physiologic events
influencing PEP. The effect of these outliers was to
decrease correlations of PEP with the outcome mea-
sures. Fourth, we programmed the software to calculate
ΔAUC by identifying the smallest and largest AUC in
successive 3-second time intervals. If this interval is
shorter than the respiratory cycle, calculated PEP will
underestimate PP; the inverse will apply if the interval is
longer than the respiratory cycle. The former appears to
apply overall because the median respiratory rates were
25/min at baseline and 24/min at 2 and 4 hours. We
recognize the need to incorporate into this evolving
technology a method for respiratory rate detection that
will then allow gating the interrogation interval more
precisely with the respiratory cycle. Lastly, there was
v e r yl i t t l ec h a n g ei nP E P ,% F E V 1 a n dR i n tf r o m0t o2
to 4 hours. This may have been because those subjects
remaining in the PED at 2 and 4 hours were minimally
improved as the reason for not being discharged and,
thus, had little change in PEP as a group.
Conclusions
The results of this study indicate that PEP has criterion
validity and responsiveness in pediatric patients with
acute asthma exacerbations. Incorporation of this tech-
nology into contemporary pulse oximeters may provide
clinicians improved parameters with which to make
clinical assessments of asthma severity and response to
treatment, particularly in patients who cannot perform
spirometry because of young age or severity of illness. It
might also allow for earlier recognition and improved
management of other disorders leading to elevated pul-
sus paradoxus.
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